What Colifoam 10% Treats: Main Uses and Benefits

Colifoam 10% is a prescription-only medication indicated for the topical management of inflammation affecting the lower gastrointestinal area. Its primary therapeutic role is as an adjunct treatment for certain inflammatory conditions of the rectal mucosa.

---

Quick Facts

• Condition Addressed: Ulcerative proctitis, a form of inflammatory bowel disease (IBD).
• Effect: Aims to help reduce local inflammation in the affected rectal area.
• Benefit: May assist in managing associated symptoms like rectal discomfort and urgency.

---

The formulation is primarily utilized for the topical treatment of distal ulcerative colitis and closely associated conditions such as procto-sigmoiditis and granular proctitis. These conditions involve inflammation in the rectum and lower sigmoid colon, which may present with symptoms including rectal pain, bleeding, and tenesmus (a frequent urge to empty the bowel).

Colifoam 10% works locally to support the reduction of inflammation in the rectal lining. By assisting in the localized reduction of the inflammatory response, the medication may provide relief from the associated disease features. It is often considered for use in patients who cannot retain other forms of rectal treatment, offering an alternative administration approach for localized management. This medicine is intended to be used as a component of a comprehensive treatment plan supervised by a healthcare professional.

Absolute Contraindications

Colifoam 10% (Hydrocortisone Acetate Rectal Foam) must not be used by patients who have a known hypersensitivity to the active ingredient or any excipients in the formulation. Use is strictly contraindicated in the presence of specific local gastrointestinal conditions, including bowel obstruction, rectal perforation, abscess, fresh intestinal anastomoses, extensive fistulas and sinus tracts, and peritonitis. Furthermore, official regulatory documents state that individuals with active local or systemic infections, such as fungal, tuberculous, or certain viral infections (e.g., anal warts or ocular herpes simplex), are ineligible.

Conditional and Restricted Use

Use of Colifoam 10% requires caution in patients with existing systemic comorbidities that may increase risk. These conditions include impaired hepatic (liver) or renal (kidney) function, diabetes, hypertension, and congestive heart failure. Caution is also advised for patients with active or latent peptic ulcers, diverticulitis, osteoporosis, and pre-existing glaucoma.

Age and Life-Stage Eligibility

For pediatric patients, prolonged use is not recommended due to the officially documented risk of temporarily slowed growth. Older adults may exhibit increased sensitivity to potential effects. The medicine is classified for use only when clearly needed during pregnancy, and its use is not recommended for women who are breastfeeding unless specifically advised.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for the hydrocortisone component of Colifoam 10% as stated in government regulatory labeling. The interaction profile is structured around combinations that require close monitoring and specific, formal restrictions.

Restrictions and Contraindicated Procedures

Due to the medication's properties as a corticosteroid, the co-administration of live vaccines is formally prohibited during therapy, a restriction documented in regulatory safety data. Furthermore, other types of immunization procedures are generally advised to be avoided, as they may lead to an impaired immunological response. The concurrent use of Amphotericin B injection is restricted because it has been associated with clinically significant outcomes, including reports of cardiac enlargement and congestive heart failure, related to severe potassium loss.

Interactions Affecting Electrolyte Balance and Exposure

The simultaneous use of this medicine with other potassium-depleting agents, such as diuretics, increases the risk of developing hypokalemia (low potassium levels). Official labeling requires patients taking these combinations to be closely observed. A specific interaction has also been documented with Aminoglutethimide. Co-administration of this substance may lead to a loss of corticosteroid-induced adrenal suppression, an official outcome described in the prescribing information, which suggests an alteration to the intended regulatory effect of the steroid compound.

The mechanism of action for Colifoam 10% (hydrocortisone acetate) is centered on its local anti-inflammatory and immunosuppressive activity within the rectum and distal colon.

Targeting Intracellular Glucocorticoid Receptors

The active component, hydrocortisone, enters mucosal cells and binds to intracellular glucocorticoid receptors (GRs). This drug-receptor complex modulates gene transcription, which is the foundational mechanistic domain for corticosteroids. This action is critical for altering the genetic instructions that dictate the production of various inflammatory and anti-inflammatory proteins, resulting in a modification of immune cell activity.

Modulating Inflammatory Signaling Cascades

Through its action on gene expression, the drug suppresses multiple inflammatory signaling cascades. Key effects include inhibiting the release of inflammatory mediators, such as prostaglandins and leukotrienes, by blocking the enzyme Phospholipase A2 ( PLA2). This interference with upstream molecular steps contributes to the modulation of pathway dynamics and decreases the migration of immune cells.

Localized Topical Action

The foam formulation ensures localized topical action, concentrating the drug's anti-inflammatory power directly in the rectal and distal colonic tissue. This strategic delivery maximizes the concentration of the corticosteroid at the site of inflammation while minimizing systemic exposure, allowing for a targeted pathway adjustment and limiting diffusion of the active moiety to other systems.

Administration Guidelines: Colifoam 10%

Colifoam 10% is formally designated for intra-rectal administration only, utilizing its specialized rectal foam dosage form. The medicine must be dispensed solely with the accompanying single-use applicator, not by inserting the aerosol canister itself. The required dose is one full applicator of the foam, which delivers approximately 80 mg of hydrocortisone (90 mg hydrocortisone acetate) per use.

Official Dosing and Schedule

Feature	Official Labeled Regimen
Initial Frequency	Once or twice daily
Initial Duration	Typically two to three weeks
Maintenance/Tapering	Frequency may be reduced to every second day
Dose Adjustment	Long-term use requires gradual withdrawal (tapering) upon cessation

Contextual Use and Procedural Conditions

The standard initial regimen of one applicator full once or twice daily is intended for use in adults, children, and the elderly. The intensive schedule should be discontinued if clinical improvement is not apparent within the initial two-to-three-week course.

For proper administration, the canister must be shaken vigorously before filling the applicator. The dose is typically timed after a bowel movement to enhance retention and stability, with the evening dose often scheduled immediately prior to bedtime.

Research evidence / Overview of Studies for Colifoam 10%

---

Evidence for Use in Ulcerative Proctitis and Proctosigmoiditis

The research base for Colifoam 10% primarily includes short-term Randomized Controlled Trials (RCTs). These studies were set up to examine outcomes associated with the use of the topical foam in adults with ulcerative proctitis and proctosigmoiditis, conditions characterized by inflammation that is limited to the rectum and sometimes the lower sigmoid colon. The trials focused on outcomes related to physical discomfort and inflammatory or irritative states. Researchers monitored patient-reported outcomes and physical signs such as rectal bleeding, urgency, and frequency of bowel movements in research exploring how symptoms change over time over a limited period.

Studies reported measurements of changes observed during the study period. This evidence contributes to understanding how patients reported their experience when using the formulation. The findings describe patterns observed in the studies, including the proportion of patients meeting the definition of clinical remission after the short-term treatment phase. The evidence describes symptom patterns in conditions characterized by fluctuating or episodic manifestations.

---

Comparison to Placebo and Other Topical Treatments

The overall evidence landscape includes trials where Colifoam 10% was compared to an inactive substance (placebo). These studies were used to evaluate the specific patterns associated with the topical corticosteroid class. Further comparative research was gathered in studies that explored outcomes when this formulation was evaluated relative to other localized therapies often used for distal disease, such as aminosalicylates. Research was conducted to examine patterns in outcomes related to inflammatory states when measured against other topical treatment scenarios.

---

Long-Term Studies and Follow-up Duration

A key characteristic of the research for this hydrocortisone foam formulation is the limited follow-up duration of the primary trials. The vast majority of the research was conducted during the acute phase of heightened symptom activity, typically monitoring responses over defined time intervals of 2 to 8 weeks. The follow-up durations were limited, providing insight into short-term changes but not long-term outcomes.

There is currently limited information for long-term outcomes or durability of response. Research has not fully explored whether using this topical formulation contributes to the maintenance of remission over many months or years. Long-term effects are not fully established, and this remains an area where data are still emerging and certainty remains low.

---

Evidence in Specific Patient Populations

The primary clinical trials largely focused on cohorts of adults who had mild-to-moderate active distal disease. The results apply only to the populations studied, meaning that the available evidence is predominantly derived from this specific group.

Data for certain groups remain insufficient. For instance, there is limited information available about research scenarios involving the topical foam in children or in older adults. Furthermore, evidence regarding outcomes in patients with numerous comorbid conditions or other complicating factors is not well established. Subgroup findings are uncertain, and results reflect the specific conditions under which the original studies were conducted.

---

What is Still Uncertain About the Research

The research base for Colifoam 10% includes several limitations that should be considered when reviewing the evidence. As noted, the follow-up durations were limited, and the long-term effects are not fully established. Similarly, while sample sizes were modest for some trials, the evidence quality varies across studies when considering all available systematic reviews.

Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. The evidence highlights what is known—and what is still uncertain—about this topical formulation's patterns of use and where more research may be ongoing or needed.

Key Studies & References

1. Ulcerative proctitis: an update on the pharmacotherapy and management

Common questions about Colifoam 10% (FAQ)

Q: How quickly does Colifoam 10% start working after I begin treatment?

A: According to official documentation, the purpose of this medication is to treat inflammation in the lower bowel. Studies and regulatory information indicate that initial symptom improvement for conditions like proctitis is often reported within the first five to seven days of the short-term treatment course.

Q: Is it common to experience irritation or burning when using Colifoam 10%?

A: Yes, official safety information describes local reactions at the application site as common adverse reactions. These commonly reported effects can include rectal burning, pain, or irritation. Should a patient experience severe or persistent effects, official guidance typically emphasizes the importance of consulting a healthcare professional.

Q: What should I know about potential interactions between Colifoam 10% and blood pressure medicines?

A: Official labeling describes a potential for interaction with potassium-depleting agents, which include certain medicines used for blood pressure like diuretics. Using these together may increase the risk of low potassium levels. Additionally, corticosteroids in general may cause an elevation in blood pressure.

Q: Is Colifoam 10% safe for use during pregnancy, according to official information?

A: Regulatory information indicates that the product should not be used extensively during pregnancy. For both pregnancy and breastfeeding, use must be determined by a healthcare professional after weighing the potential benefits against any risks. Safety in these specific groups remains an area where data is limited and certainty is low.

Q: Can I stop using Colifoam 10% suddenly if I feel better?

A: Abrupt discontinuation of the treatment should be avoided. Official guidelines describe a need for gradual withdrawal, or tapering, upon cessation, especially after prolonged use. The regulatory warning is based on the risk of acute adrenal insufficiency, which can occur with abrupt discontinuation as the body adjusts to the corticosteroid.

Q: Are there long-term studies on the safety of using Colifoam 10% repeatedly?

A: The research base primarily includes short-term trials, typically monitoring responses over intervals of two to eight weeks. Because of this, the long-term effects or durability of the response are not fully established. Available evidence is limited to these short-term findings.

Q: Does Colifoam 10% need to be refrigerated?

A: No, the medication must be stored upright at controlled room temperature, typically between 20^circC and 25^circC. Official instructions for this product state that refrigeration should be avoided, as the specific foam formulation may be compromised.

Q: Is Colifoam 10% used for proctitis or just ulcerative colitis?

A: The drug is officially indicated for the topical treatment of inflammation occurring in the rectal mucosa. This includes conditions such as ulcerative proctitis and proctosigmoiditis, which are limited forms of distal ulcerative colitis.

Q: Does Colifoam 10% have systemic side effects, or are they only local?

A: While the medication has a localized topical action, the possibility of systemic side effects exists, particularly with prolonged or frequent use, due to some absorption of the corticosteroid into the bloodstream. Official safety data describes the potential for both local (at the application site) and systemic effects.

Q: Can Colifoam 10% cause weight gain or changes in mood?

A: Psychiatric adverse reactions such as mood changes and depression have been reported in safety documentation for corticosteroids. Systemic effects sometimes reported with corticosteroids, such as changes in body fat distribution or appearance consistent with Cushing's syndrome, are also noted as potential risks.

Q: Are there any specific health conditions that would make someone ineligible for Colifoam 10%?

A: Official documents list several conditions as contraindications (making use ineligible). These include certain infections (fungal, viral, bacterial), intestinal obstruction, abscess, perforation, and fresh intestinal anastomoses.

Q: What happens if I forget to use Colifoam 10% at the scheduled time?

A: If a dose is missed, regulatory patient information generally advises using it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should return to the regular schedule. The guidance is to avoid using two doses at one time.

Q: Will Colifoam 10% affect my ability to drive or operate machinery?

A: The official safety profile does not specifically mention effects on driving ability. However, safety documents do report potential psychiatric adverse reactions (e.g., anxiety or mood changes) which may affect a patient's ability to concentrate or perform tasks.

Q: Is it true that Colifoam 10% should not be used if the condition is very severe?

A: Use of the medication requires caution in patients with severe ulcerative disease due to the potential for bowel perforation. Official documents suggest that delaying surgical intervention while awaiting a response in cases of severe colitis may be hazardous.

Q: Can Colifoam 10% cause a change in blood sugar levels?

A: Yes, as with other corticosteroids, the use of this medication may increase blood glucose concentrations (blood sugar levels). Therefore, the official label indicates that careful management may be needed, and dosage adjustments of anti-diabetic medications may be required for patients with diabetes.

Q: How does Colifoam 10% affect the lining of the colon?

A: The medication is a local treatment that works by exerting an anti-inflammatory and immunosuppressive effect on the rectal and distal colonic mucosa. By modulating inflammatory signaling cascades in the tissue, it reduces the swelling and irritation associated with conditions like ulcerative proctitis.

Q: Is Colifoam 10% known to interact with birth control pills?

A: Official interaction information indicates that estrogens, including those found in oral contraceptives, may decrease the breakdown of certain corticosteroids. This change could potentially lead to an increase in the effect of the foam, a pattern often associated with the need for professional oversight.

Q: What is the risk of developing a secondary infection while using Colifoam 10%?

A: Official safety information notes that use of the medication may lead to increased susceptibility to infection (e.g., viral, bacterial, fungal). Secondary infection is listed as a potential adverse reaction because the medication has immunosuppressive properties.

Q: Is the medication absorbed into the bloodstream after using Colifoam 10%?

A: Yes, hydrocortisone is absorbed to some extent into the bloodstream (systemic absorption). However, the topical foam formulation is specifically intended to minimize this absorption compared to systemic treatments like oral tablets.

Q: Why does the packaging state to avoid fire or flames while dispensing Colifoam 10%?

A: The container is an aerosol and is stored under pressure. Regulatory warnings mandate avoiding fire or flames because the propellant ingredients used in the pressurized canister may be flammable. It is also advised not to burn or puncture the container.

Q: Are there any known interactions between Colifoam 10% and common pain relievers like ibuprofen?

A: Official interaction information advises caution regarding the co-administration of corticosteroids with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen. This is due to a potential increase in the risk of gastrointestinal side effects.

Q: What is the difference in side effects between oral steroids and rectal foam steroids like Colifoam 10%?

A: The rectal foam is formulated to provide localized topical action, which is intended to minimize the amount of medicine absorbed into the body compared to oral steroids. This targeted delivery aims to reduce the potential for systemic side effects commonly associated with oral corticosteroid use.

Q: Is Colifoam 10% a permanent cure or a treatment for symptoms?

A: The product is described in regulatory documents as a topical treatment for the inflammation associated with conditions like ulcerative proctitis. It is used to achieve clinical remission during active disease states, not defined as a permanent cure for the underlying chronic condition.

Q: Can Colifoam 10% be used if a patient is already taking oral steroid tablets?

A: No specific interaction is listed, but using the foam while already taking oral steroid tablets increases the risk of cumulative systemic exposure to corticosteroids. This combination may require professional oversight due to the potential for cumulative systemic exposure.

Q: What happens if a patient accidentally uses more than the specified amount of Colifoam 10%?

A: Regulatory patient information advises against using large amounts or using the medication for a long time. Overuse is a factor that increases the likelihood of systemic absorption and the potential for side effects related to high corticosteroid exposure.

Q: Is a prescription always required to obtain Colifoam 10%?

A: Yes, Colifoam 10% is classified in major jurisdictions as a Prescription Only Medicine. This means a valid prescription from a licensed healthcare provider is always required to obtain the product.

How to Store and Dispose of Colifoam 10% (Hydrocortisone Acetate)

Official regulatory labeling dictates specific conditions for storing and disposing of Colifoam 10% rectal foam.

---

Storage Requirements

Colifoam 10% must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The container must be stored away from heat and protected from freezing. Do not store the product at temperatures above 120 F (49 C) and do not refrigerate. The medication must be kept out of the reach of children.

---

Disposal Instructions

As the container is a pressurized aerosol, it must not be punctured or incinerated. Any unused or expired product must be disposed of according to local requirements for pharmaceutical waste; it should not be disposed of in wastewater.